Doron Therapeutics
- Biotech or pharma, therapeutic R&D
Doron Therapeutics is a regenerative medicine company developing MOTYS - a Phase 3 ready, biologic drug designed to treat knee osteoarthritis symptoms and delay progression of the disease. A single injection of MOTYS provides 12 months of pain relief and improved function with the additional potential of being a disease-modifying osteoarthritis drug (DMOAD) acting to delay/reverse disease progression.
We are actively meeting with US and OUS strategic partners to evaluate potential business relationships and future commercialization of MOTYS. We are also meeting with investors to add to our syndicate funding our streamlined path to BLA approval following a recent highly positive EoPh2 meeting with FDA validating our Ph3 plans, CMC, endpoints and safety database.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}